Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label ""Patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: * cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see Warnings and Precautions (5.3 * Previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5)] . * Hypersensitivity to epirubicin hydrochloride, other anthracyclines, or anthracenediones [see Adverse Reactions (6.2)]. Patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: baseline neutrophil count < 1500 cells/mm 3; (4)."" assertion.
- association label ""Doxercalciferol is contraindicated in patients with: Hypercalcemia [see Warnings and Precautions (5.1) Vitamin D toxicity [see Warnings and Precautions (5.1) Known hypersensitivity to doxercalciferol or any of the inactive ingredients of Doxercalciferol capsules or HECTOROL injection; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported [see Warnings and Precautions (5.3) Adverse Reactions (6.2) Hypercalcemia ( 4 Vitamin D toxicity ( 4 Know hypersensitivity to doxercalciferol or any of the inactive ingredients of Doxercalciferol capsules or HECTOROL injection ( 4"" assertion.
- association label ""Well established anuria due to severe renal disease. Severe pulmonary congestion or frank pulmonary edema. Active intracranial bleeding except during craniotomy. Severe dehydration. Progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia. Progressive heart failure or pulmonary congestion after institution of mannitol therapy. Do not administer to patients with a known hypersensitivity to mannitol."" assertion.
- association label "Myocardial infarction, history of myocardial infarction, coronary insufficiency, angina, or other evidence suggestive of coronary artery disease; hypersensitivity to phentolamine or related compounds." assertion.
- association label ""* Medullary Thyroid Carcinoma TANZEUM is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)] * Hypersensitivity TANZEUM is contraindicated in patients with a prior serious hypersensitivity reaction to albiglutide or to any of the product components. Serious hypersensitivity reactions including angioedema have been reported with TANZEUM [see Warnings and Precautions (5.4)]. * 4 * 4 5.4"" assertion.
- association label "Pyridostigmine Bromide Extended release Tablets is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below." assertion.
- association label "Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction." assertion.
- association label "Sevoflurane, USP can cause malignant hyperthermia. It should not be used in patients with known sensitivity to sevoflurane, USP or to other halogenated agents nor in patients with known or suspected susceptibility to malignant hyperthermia." assertion.
- association label "BREVITAL is contraindicated in patients in whom general anesthesia is contraindicated, in those with latent or manifest porphyria, or in patients with a known hypersensitivity to barbiturates." assertion.
- association label ""Methazolamide tablets therapy is contraindicated in situations in which sodium and/or potassium serum levels are depressed, in cases of marked kidney or liver disease or dysfunction, in adrenal gland failure, and in hyperchloremic acidosis. In patients with cirrhosis, use may precipitate the development of hepatic encephalopathy. Long-term administration of methazolamide is contraindicated in patients with angle-closure glaucoma, since organic closure of the angle may occur in spite of lowered intraocular pressure."" assertion.
- association label "Transderm Scop is contraindicated in persons who are hypersensitive to the drug scopolamine or to other belladonna alkaloids, or to any ingredient or component in the formulation or delivery system, or in patients with angle-closure (narrow angle) glaucoma." assertion.
- association label ""Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Methscopolamine Bromide 2.5 mg Tablets/Methscopolamine Bromide 5 mg Tablets are contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs."" assertion.
- association label ""Hydroxyurea is contraindicated in patients with marked bone marrow depression, i.e., leukopenia (< 2500 WBC) or thrombocytopenia (< 100,000), or severe anemia. Hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation."" assertion.
- association label "Barbiturates are contraindicated in patients with known barbiturate sensitivity. Barbiturates are also contraindicated in patients with a history of manifest or latent porphyria." assertion.
- association label "Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug." assertion.
- association label ""SORILUX Foam should not be used by patients with known hypercalcemia. Do not use in patients with known hypercalcemia. ( 4"" assertion.
- association label ""Carteolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS WARNINGS"" assertion.
- association label "Seconal Sodium is contraindicated in patients who are hypersensitive to barbiturates. It is also contraindicated in patients with a history of manifest or latent porphyria, marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident." assertion.
- association label "Histamine should not be injected into individuals with hypotension, severe hypertension, severe cardiac, pulmonary, or renal disease. Not to be used for diagnosis of pheochromocytoma or to test the ability of the gastric mucosa to secrete hydrochloric acid." assertion.
- association label ""Primidone tablet is contraindicated in: 1) patients with porphyria and 2) patients who are hypersensitive to phenobarbital (see CLINICAL PHARMACOLOGY"" assertion.
- association label ""Levobunolol Hydrochloride Ophthalmic Solution is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS WARNINGS"" assertion.
- association label "Known sensitivity to Isoflurane, USP or to other halogenated agents. Known or suspected genetic susceptibility to malignant hyperthermia." assertion.
- association label ""BELSOMRA is contraindicated in patients with narcolepsy. Do not use in patients with narcolepsy ( 4"" assertion.
- context label "adults" assertion.
- association label "Clozapine is not recommended for OCD due to poor evidence of efficacy [170]. In addition, several case reports and clinical studies support the association of clozapine with worsening or onset of obsessive-compulsive symptoms in patients with a psychotic disorder [171-176]. At least 20% of individuals treated with clozapine (and other antiserotonergic antipsychotics) would experience worsening or emergence of obsessive-compulsive symptoms [177], which are dose-related [178] and generally reversible upon discontinuation of clozapine treatment and switch to a different antipsychotic [179]" assertion.
- context label "adults" assertion.
- association label "Citalopram proved to be effective in the treatment of OCD [55], with best results at doses of 60 mg/day [56], which correlated with improvements on psychosocial functioning, depressive symptoms, obsessive thoughts, repetitive behavior, and anxiety. It showed good tolerability [57] and appeared to be effective in patients with refractory OCD [58]." assertion.
- context label "adults" assertion.
- association label "Ketamine has emerged as a rapid-acting antidepressant, though controversy remains whether sufficient data exist to justify its use outside of research protocols. In October 2014, the authors' institution began providing ketamine as an off-label therapy on a case-by-case basis for patients unable to participate in research protocols." assertion.
- context label "adults" assertion.
- association label "The most common off-label uses were for manic-depressive psychosis treated with citalopram and primary insomnia treated with trazodone." assertion.
- association label "The most common off-label uses were for manic-depressive psychosis treated with citalopram and primary insomnia treated with trazodone. Several patient and clinician characteristics were positively associated with off-label prescribing, including seeing a psychiatrist (OR: 1.06, 95% CI, 1.01–1.12; p = 0.03) instead of another type of clinician, the office visit taking place in the Western region of the country (OR: 1.09, 95% CI, 1.01–1.17; p = 0.02), and the patient having 3 or more chronic conditions (OR: 1.12, 95% CI, 1.02–1.14; p = 0.003)." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "Information only available from Table 3" assertion.
- MONDO_0001866 label "bipolar I disorder" assertion.
- MONDO_0001866 label "Bipolar I Disorder" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "The nicotinic-acetylcholine receptor (nAchR)- antagonist mecamylanine has been found to reduce the stimulus produced by ethanol in human lab studies. The nAchR-antagonist varenicline has also displayed positive effect in reducing alcohol consumption in multiple clinical trials. In this 12- week double-blind trial, participants (n 1⁄4 126) were randomized to either mecamylamine (10 mg daily) or placebo. No medication effect was found for reducing heavy drinking days (HDD) or alcohol craving. Smoking status had no effect on the results. The authors suggest that broad-spectrum nAchR-antagonists may not be beneficial in treat- ing AUD" assertion.
- association label "Citicoline was well tolerated but did not reduce alcohol consump- tion compared with placebo as measured by the time line follow back-method. The authors conclude that although citicoline has shown promise on many fields, it did not prove beneficial in treating AUD in these patients" assertion.
- association label "nly a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- association label "While alcohol induces an increase of dopamine, ondansetron reduces the release of the neurotransmitter by blocking the 5-HT3 receptors. Several studies investigated the effectiveness of ondansetron by dividing alcoholic individuals into two subgroups based on their genotype for the promoter region of the SLC6A4 gene coding for the serotonin transporter (5-HTTLPR L/S polymorphism). The study showed that the patients with the LL genotype treated with ondansetron responded better in terms of alcohol amount and days of abstinence, compared to the other subgroups. Based on these results, researchers have further investigated genotype LL carriers, by analyzing the role of a functional polymorphism of the SLC6A4 gene (rs1042173 [T/G] SNP). The result was that individuals who carry both 5-HTTLPR LL polymorphism and rs1042173 TT polymorphism, treated with ondansetron at the dosage of 0.5 mg/die, present a more effective response to the drug. Unfortunately, the sample of this exploratory study was too small to be validated." assertion.
- context label "adults" assertion.
- association label "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia. " assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia. " assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "With this rapidly growing evidence of a fast-acting antidepressant such as ketamine, as well as its efficacy in treatment-resistant cases of depression, off-label use has become popular in certain settings. " assertion.
- context label "elderly" assertion.
- association label "Trazodone, the most sedating atypical antidepressant, is widely used as an off-label hypnotic especially in the elderly. Although generally considered safe, it can potentially inhibit midbrain dopaminergic neurotransmission leading to the emergence of extrapyramidal adverse effects. Two previous cases of trazodone-induced parkinsonism have been described after its prolonged use as an antidepressant; however, there is no published case of secondary parkinsonism caused by trazodone in a nondepressed person after its use as a hypnotic. Here, we present a case of rapid development of bradykinetic-rigid parkinsonism temporally linked to the use of trazodone as a hypnotic in a nondepressed elderly man" assertion.
- association label ""The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders." "The majority of children prescribed risperidone were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) or conduct disorder." " assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "Antipsychotic medications are increasingly prescribed off-label to children for the treatment of disruptive behavior disorders, anxiety and depression." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Quetiapine was mainly prescribed for neurotic disorder or depression, while aripiprazole was prescribed most frequently for conduct disorder or neurotic disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- association label "It is licensed to treat depression, but it is also commonly used off-label to treat insomnia." assertion.
- context label "adults" assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Children" assertion.
- association label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" assertion.
- obesityWith-metabolic-abnormality label "obesity together with metabolic abnormality" assertion.
- spi label "Obesity when accompanied by metabolic abnormality is closely associated with knee osteoarthritis." assertion.
- ex-obesity-together-with-metabolic-abnormality label "obesity together with metabolic abnormality" assertion.
- obesityTogetherWithMetabolicAbnormality label "obesity together with metabolic abnormality" assertion.
- spi label "Obesity when accompanied by metabolic abnormality is closely associated with knee osteoarthritis." assertion.
- transcription-of-stmn2 label "transcription of stmn2" assertion.
- spi label "The cortex size of humans does not relate to their social group size" assertion.
- spi label "Sonic hedgehog signalling pathway is an essential regulator of astrocytes development." assertion.
- spi label "Sometimes Vitamin A targets are the same as genes associated with CAKUT" assertion.
- adherenceToTheFAIRGuidingPrinciples label "adherence to the FAIR Guiding Principles" assertion.
- spi label "In the context of Digital Humanities research, usage of the Linked Data Scopes ontology contributes to transparency of the research." assertion.
- spi label "The protein TDP-43 represses cryptic exon inclusion in the gene UNC13A." assertion.
- expression-of-genes-IRX3-and-IRX5 label "expression of genes IRX3 and IRX5" assertion.
- regulatory-element-within-the-first-intron-of-FTO label "regulatory element within the first intron of FTO" assertion.
- the-latest-release-of-openbiodiv label "The latest release of OpenBiodiv" assertion.